Nontoxic Goiter (NTG) and Radioiodine: What Do Patients Think About It? Quality of Life in Patients with NTG Before and After 131-I Therapy

• Main Authors: Sonia Kaniuka-Jakubowska, Anna Lewczuk, Mikołaj Majkowicz, Maciej Piskunowicz, Krystyna Mizan-Gross, Adam Zapaśnik, Mariusz Kaszubowski, Piotr Lass, Krzysztof Sworczak
• Format: Article
• Language: English
• Published: Frontiers Media S.A. 2018-04-01
• Series: Frontiers in Endocrinology
• Subjects: nontoxic goiter; radioiodine; quality of life; 36-item Short Form; life quality
• Online Access: http://journal.frontiersin.org/article/10.3389/fendo.2018.00114/full

ObjectiveDespite numerous publications regarding nontoxic goiter (NTG) treatment and an increasing interest in patients’ quality of life, few studies present the outcome of 131-I treatment from the patients’ perspective. Our study’s main aim was to verify whether there is any improvement in life quality following 131-I treatment.Materials and methodsThirty-five patients with NTG qualified to participate in the study. All patients completed a Thyroid-Related Health-Related Quality of Life (Thy-R-HRQoL) questionnaire created by us and the Medical Outcomes Study 36-item Short Form (SF-36), right before and 1 year after 131-I.ResultsWe observed an improvement in six out of eight SF-36 and three out of seven Thy-R-HRQoL domains. In comparison with the control group, we observed worse results in two out of eight, prior to treatment, and one out of eight SF-36 afterward, as well as in all Thy-R-HRQoL domains. We did not find any correlation between improvement of Thy-R-HRQoL and SF-36 and goiter size reduction, except for Bodily Pain. There was also no correlation between improvement of SF-36 and Thy-R-HRQoL domains, and goiter size before treatment. The older the patient, the less noticeable improvement was observed in Physical and Social Functioning, and Vitality in SF-36, but age had no influence on the assessment by Thy-R-HRQoL.ConclusionRadioiodine treatment improves life quality in patients with NTG. Use of the Health-Related Quality of Life questionnaire should be taken into consideration when evaluating life quality of patients with NTG. Relentless pursuit of maximal goiter size reduction in 131-I treatment is worth consideration. In our study, life quality improvement did not depend directly on the goiter size reduction. Life quality improvement after 131-I might not depend on initial goiter size, and for certain domains of SF-36 might be less clearly expressed in older patients.